H.C. Wainwright Assumes Pluristem Therapeutics (PSTI) at Buy

H.C. Wainwright assumed coverage on Pluristem Therapeutics (NASDAQ: PSTI) with a Buy rating and a price target of $3.50.

Analyst Swayampakula Ramakanth said, "Pluristem is developing allogeneic vascular and muscle regeneration therapies based on its proprietary PLX platform. Unlike other cell-based regenerative medicine products, PLX can be used directly off-the-shelf with no additional manipulation by the physician. PLX also has low immunogenicity, does not require HLA-matching, and does not integrate with the host tissue. PLX-PAD, the company’s lead product, is currently being developed for the treatment of Critical Limb Ischemia (CLI), Intermittent Claudication (IC), and muscle injury resulting from hip replacement surgery. Pluristem has reported encouraging earlystage results for all three indications and is pursuing expedited approvals for the treatment of CLI. We expect PLX-PAD to reach the market in 2018 and achieve risk-adjusted sales of $270M by 2026."

For an analyst ratings summary and ratings history on Pluristem Therapeutics click here. For more ratings news on Pluristem Therapeutics click here.

Shares of Pluristem Therapeutics closed at $1.48 yesterday.

You May Also Be Interested In

• Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
• Opthea Ltd. (OPT) PT Raised to $18 at Oppenheimer
• Boston Scientific (BSX) PT Raised to $77 at Oppenheimer